Taipei, Taiwan | Fund Name | Location |
| 7 Global Capital | California, San Francisco, United States |
| AgTech Innovation Network | - |
| Baize Capital | Beijing, Beijing, China |
| Cockrell Investment Partners | Houston, Texas, United States |
| Form Capital | - |
| Honeywell International | Morristown, New Jersey, United States |
| JT Venture Partners | Burlington, Massachusetts, United States |
| Lauder Partners | Atherton, California, United States |
| NCD | - |
| Novel Growth Partners | Kansas, Overland Park, United States |
| Parinama Cultural Development Foundation | - |
| Qunanda Zichan | China, Guangdong, Shenzhen |
| RCM Business | Bhilwara, India, Rajasthan |
| Shenzhen Qianhai Lichangrong Asset Investment Management | - |
| SIOS Technology Corp. | California, San Mateo, United States |
| Star Farm Ventures | New York, New York, United States |
| Starr Companies | New York, New York, United States |
| UCCVR | China, Shanghai |
| Vang Capital | England, London, United Kingdom |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Elixiron Immunotherapeutics | $27M | 23 Aug 2021 | New Taipei, Taiwan |
– Elixiron Immunotherapeutics from San Francisco develops therapeutics for cancer, neurological diseases and inflammatory disorders.
– The company closed a $27m Series A-1 extension financing round.
– The round was jointly led by Pangu Capital (a new investor) and Taiwania Capital (an existing investor) and was joined by further new investors, including DCI Partners of Daiwa Securities Group, Mega International Commercial Bank, Fubon Financial Holdings and Hong Tai Electric Industrial, as well as other existing investors such as China Development Capital Industrial Bank (CDIB) Capital Group.
– The company intends to use the funds to advance phase 1 trials of two pipeline candidates and take three immuno-oncology assets towards IND applications.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Elixiron Immunotherapeutics | $27M | 23 Aug 2021 | New Taipei, Taiwan |
